ATLANTA — Weekly injections of the glucagon-like peptide (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic), relieves symptoms in patients with heart failure with preserved ejection fraction ...
Heart failure with preserved ejection fraction (HFpEF) can prove a complex problem for clinicians — its prevalence is increasing, it mimics many other conditions, and it can have a devastating impact ...
Please provide your email address to receive an email when new articles are posted on . Semaglutide 2.4 mg significantly reduced HF symptom burden among adults with HF with preserved ejection fraction ...
Phenotyping in HFpEF aids in tailoring therapies, addressing comorbidities, and improving patient outcomes. Artificial intelligence models effectively diagnose HFpEF and predict mortality, enhancing ...
Please provide your email address to receive an email when new articles are posted on . Tirzepatide reduced outcomes and symptoms for patients with HFpEF and obesity vs. placebo. The safety profile ...
CHICAGO, IL—Tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and worsening heart failure events by nearly 40% over a median follow-up of roughly 2 years in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results